U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595003) titled 'Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia' on May 12.
Brief Summary: The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.
Study Start Date: Dec. 12, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Cholecystitis
Biliary Dyskinesia
Intervention:
DRUG: 4-MUST
128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.
DRUG: Placebo
Placebo tablet.
Recruitment Status: RECRUITING
Sponsor: Valenta Pharm JSC
Published by HT Digital ...